De Burlo Group’s Supernus Pharmaceuticals SUPN Stock Holding History

De Burlo Group’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-36,500	Closed	-$2.18M	–	122
2018 Q2	$2.18M	Buy	+36,500	New	+$1.89M	0.46%	55

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return

De Burlo Group's SUPN Position: Q3 2018 in Review

De Burlo Group sold out of Supernus Pharmaceuticals (SUPN) in Q3 2018, closing a stake of 36,500 shares — an estimated $2.18M sold.

De Burlo Group first reported a position in SUPN in Q2 2018 and held it in 1 quarter. The position peaked at $2.18M in Q2 2018. 288 funds tracked by Wall St. Rank hold SUPN as of Q3 2018.

De Burlo Group reported no remaining Supernus Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
De Burlo Group sold 36,500 Supernus Pharmaceuticals shares in Q3 2018, an estimated $2.18M.
De Burlo Group first reported a position in Supernus Pharmaceuticals in Q2 2018 and held it in 1 quarter.
De Burlo Group's Supernus Pharmaceuticals position peaked at $2.18M in Q2 2018.
288 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2018.

Based on De Burlo Group's 13F filing for Q3 2018, filed 8 Nov 2018.